Details
Stereochemistry | RACEMIC |
Molecular Formula | C36H41N3O6 |
Molecular Weight | 611.7272 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
COC(=O)C1=C(C)NC(C)=C(C1C2=CC=CC(=C2)[N+]([O-])=O)C(=O)OC(C)(C)CN(C)CCC(C3=CC=CC=C3)C4=CC=CC=C4
InChI
InChIKey=ZDXUKAKRHYTAKV-UHFFFAOYSA-N
InChI=1S/C36H41N3O6/c1-24-31(34(40)44-6)33(28-18-13-19-29(22-28)39(42)43)32(25(2)37-24)35(41)45-36(3,4)23-38(5)21-20-30(26-14-9-7-10-15-26)27-16-11-8-12-17-27/h7-19,22,30,33,37H,20-21,23H2,1-6H3
DescriptionCurator's Comment: description was created based on several sources, including
https://www.drugs.com/history/lercanidipine.html | https://www.ncbi.nlm.nih.gov/pubmed/27794423
Curator's Comment: description was created based on several sources, including
https://www.drugs.com/history/lercanidipine.html | https://www.ncbi.nlm.nih.gov/pubmed/27794423
Lercanidipine is antihypertensive drugs which acts by blocking L-type calcium channels, allowing relaxation and opening of blood vessels. Lercanidipine exists as a racemate, with anti-hypertensive activity residing primarily in S-enantiomer. NDA for lercanidipine was submitted to FDA in 2002 by Forest Laboratories, but FDA refused to approve the drug, and lercanidipine is not marketed in USA. Lercanidipine is also investigated in preclinical models of epilepsy and ischemic stroke.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26673531
Curator's Comment: Active in a preclinical models of epilepsy on mice
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2095229 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16173926 |
2.2 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | ZANIDIP Approved UseLercanidipine is indicated for the treatment of mild to moderate essential hypertension |
|||
Primary | Unknown Approved UseUnknown |
|||
Palliative | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Lercanidipine: a review of its use in hypertension. | 2000 Nov |
|
Nephroprotective effect of treatment with calcium channel blockers in spontaneously hypertensive rats. | 2000 Sep |
|
Tolerability of long-term treatment with lercanidipine versus amlodipine and lacidipine in elderly hypertensives. | 2002 Nov |
|
Lercanidipine and losartan effects on blood pressure and fibrinolytic parameters. | 2006 Apr |
|
Lercanidipine in the treatment of hypertension. | 2007 Mar |
Sample Use Guides
The recommended dosage is 10 mg orally once a day at least 15 minutes before meals; the dose may be increased to 20 mg depending on the individual patient's response. In preclinical models lercanidipine is administered intraperitoneally.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16173926
Lercanidipine demonstrated vasodilation effect in isolated vessel ring obtained from human arteria mammaria preparation (EC50 approx. 1 nM). Isolated vessel rings were precontracted by 0.3 mol/L prostaglandin F2.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
C09DB08
Created by
admin on Sat Dec 16 17:55:00 GMT 2023 , Edited by admin on Sat Dec 16 17:55:00 GMT 2023
|
||
|
NCI_THESAURUS |
C333
Created by
admin on Sat Dec 16 17:55:00 GMT 2023 , Edited by admin on Sat Dec 16 17:55:00 GMT 2023
|
||
|
WHO-ATC |
C08CA13
Created by
admin on Sat Dec 16 17:55:00 GMT 2023 , Edited by admin on Sat Dec 16 17:55:00 GMT 2023
|
||
|
WHO-ATC |
C09BB02
Created by
admin on Sat Dec 16 17:55:00 GMT 2023 , Edited by admin on Sat Dec 16 17:55:00 GMT 2023
|
||
|
WHO-VATC |
QC09BB02
Created by
admin on Sat Dec 16 17:55:00 GMT 2023 , Edited by admin on Sat Dec 16 17:55:00 GMT 2023
|
||
|
WHO-VATC |
QC08CA13
Created by
admin on Sat Dec 16 17:55:00 GMT 2023 , Edited by admin on Sat Dec 16 17:55:00 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C060343
Created by
admin on Sat Dec 16 17:55:00 GMT 2023 , Edited by admin on Sat Dec 16 17:55:00 GMT 2023
|
PRIMARY | |||
|
V7XTJ4R0BH
Created by
admin on Sat Dec 16 17:55:00 GMT 2023 , Edited by admin on Sat Dec 16 17:55:00 GMT 2023
|
PRIMARY | |||
|
LERCANIDIPINE
Created by
admin on Sat Dec 16 17:55:00 GMT 2023 , Edited by admin on Sat Dec 16 17:55:00 GMT 2023
|
PRIMARY | |||
|
DB00528
Created by
admin on Sat Dec 16 17:55:00 GMT 2023 , Edited by admin on Sat Dec 16 17:55:00 GMT 2023
|
PRIMARY | |||
|
4157
Created by
admin on Sat Dec 16 17:55:00 GMT 2023 , Edited by admin on Sat Dec 16 17:55:00 GMT 2023
|
PRIMARY | |||
|
6971
Created by
admin on Sat Dec 16 17:55:00 GMT 2023 , Edited by admin on Sat Dec 16 17:55:00 GMT 2023
|
PRIMARY | |||
|
100000092283
Created by
admin on Sat Dec 16 17:55:00 GMT 2023 , Edited by admin on Sat Dec 16 17:55:00 GMT 2023
|
PRIMARY | |||
|
65866
Created by
admin on Sat Dec 16 17:55:00 GMT 2023 , Edited by admin on Sat Dec 16 17:55:00 GMT 2023
|
PRIMARY | |||
|
C81687
Created by
admin on Sat Dec 16 17:55:00 GMT 2023 , Edited by admin on Sat Dec 16 17:55:00 GMT 2023
|
PRIMARY | |||
|
CHEMBL250270
Created by
admin on Sat Dec 16 17:55:00 GMT 2023 , Edited by admin on Sat Dec 16 17:55:00 GMT 2023
|
PRIMARY | |||
|
100427-26-7
Created by
admin on Sat Dec 16 17:55:00 GMT 2023 , Edited by admin on Sat Dec 16 17:55:00 GMT 2023
|
PRIMARY | |||
|
DTXSID2048327
Created by
admin on Sat Dec 16 17:55:00 GMT 2023 , Edited by admin on Sat Dec 16 17:55:00 GMT 2023
|
PRIMARY | |||
|
m6770
Created by
admin on Sat Dec 16 17:55:00 GMT 2023 , Edited by admin on Sat Dec 16 17:55:00 GMT 2023
|
PRIMARY | Merck Index | ||
|
SUB08437MIG
Created by
admin on Sat Dec 16 17:55:00 GMT 2023 , Edited by admin on Sat Dec 16 17:55:00 GMT 2023
|
PRIMARY | |||
|
135056
Created by
admin on Sat Dec 16 17:55:00 GMT 2023 , Edited by admin on Sat Dec 16 17:55:00 GMT 2023
|
PRIMARY | RxNorm |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)